Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 16/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2071259 | 0.89 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3NR3C2P2RX7 | |
| SCHEMBL2073944 | 0.85 | SLC6A2 (0.66) | SLC6A2SLC6A4 | |
| SCHEMBL2074072 | 0.85 | SLC6A2 (0.66) | SLC6A2SLC6A4 | |
| SCHEMBL2072658 | 0.85 | SLC6A2 (0.66) | SLC6A2SLC6A4 | |
| SCHEMBL2074246 | 0.82 | SLC6A2 (0.54) | SLC6A2SLC6A4NR3C2 | |
| SCHEMBL2073496 | 0.81 | SLC6A2 (0.70) | SLC6A2SLC6A4NR3C2 | |
| SCHEMBL2073733 | 0.81 | SLC6A2 (0.50) | SLC6A2SLC6A4NR3C2P2RX7 | |
| SCHEMBL2072805 | 0.79 | SLC6A4 (0.50) | SLC6A2SLC6A4NR3C2 | |
| SCHEMBL2075060 | 0.73 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL2073862 | 0.70 | SLC6A2 (0.58) | SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863305-B2 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | ROCHE PALO ALTO LLC (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863305-B2 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | ROCHE PALO ALTO LLC (US) | 2011-01-04 | — | — | US | disclosed |
| US-7863305-B2 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | ROCHE PALO ALTO LLC (US) | 2011-01-04 | — | — | US | disclosed |
| EP-1756054-B1 | 3-AMINO-1-ARYLPROPYL INDOLES AS MONOAMINE REUPTAKE INHIBITOR | HOFFMANN LA ROCHE (CH) | 2010-03-31 | — | — | EP | disclosed |
| US-20060025467-A1 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | ROCHE PALO ALTO LLC | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025467-A1 | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitors | TPH1, HTR1A, HTR3A | SLC6A2 9/4885SLC6A4 14/4885SLC6A3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.